

Special Issue

Predictive and Prognostic Factors in Mesothelioma

Message from the Guest Editors

Malignant pleural mesothelioma is an aggressive disease with poor prognosis. Recently the use of immunotherapy in first line with Nivolumab and Ipilimumab have improved the overall survival of patients with inoperable disease compared to chemotherapy. To date, it is unclear which factors might play a role in prediction of therapy-responses and prognosis for this disease. This special issue will cover a broad range of data regarding the predictive and prognostic role of:

- Clinical features
- Laboratory values
- Imaging features
- Molecular signatures
- Tumor microenvironment characteristics

Guest Editors

Dr. Federica Grosso

Dr. Alessandra Curioni-Fontecedro

Dr. Stefanie Hiltbrunner

Deadline for manuscript submissions

closed (20 April 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/118512

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)